Critical targets of protein kinase C in differentiation of tumour cells

Biochemical Pharmacology

Volumn 58, Issue 3, 1999, Pages 383-388

  Watters, Dianne J ^a   Parsons, Peter G ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Bistratene A; Cell cycle; Melanogenesis; PKC isoforms; Signal transduction; Stathmin; Transcription factors

Indexed keywords

BISTRATENE A; BRYOSTATIN 1; ENZYME ACTIVATOR; ISOENZYME; PROTEIN KINASE C; STATHMIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; DRUG RESEARCH; GENE ACTIVATION; HUMAN; HUMAN CELL; MELANOGENESIS; MELANOMA CELL; NOTE; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0033014353     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00063-5     Document Type: Review

References (63)

1. Mellor H and Parker PJ, The extended protein kinase C superfamily. Biochem J 332: 281-292, 1998.
2. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S and Foster DA, Tumour promotion by depleting cells of protein kinase Cδ. Mol Cell Biol 17: 3418-3428, 1997.
3. Keenan C, Goode N and Pears C, Isoform specificity of activators and inhibitors of protein kinase C γ and δ. FEBS Lett 415: 101-108, 1997.
4. Dekker LV and Parker PJ, Regulated binding of the protein kinase C substrate GAP-43 to the V0/C2 region of protein kinase C-δ. J Biol Chem 272: 12747-12753, 1997.
5. Kielbassa K, Müller H-J, Meyer HE, Marks F and Gschwendt M, Protein kinase Cδ-specific phosphorylation of the elongation factor eEF-lα and an eEF-lα peptide at threonine 431. J Biol Chem 270: 6156-6162, 1995.
6. Maizels ET, Peters CA, Kline M, Cutler RE Jr, Shanmugam M and Hunzicker-Dunn M, Heat-shock protein-25/27 phosphor-ylation by the δ isoform of protein kinase C. Biochem J 332: 703-712, 1998.
7. Cacace AM, Ueffing M, Philipp A, Han EK-H, Kolch W and Weinstein IB, PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 13: 25172526, 1996.
8. Deacon EM, Pongracz J, Griffiths G and Lord JM, Isoenzymes of protein kinase C: Differential involvement in apoptosis and pathogenesis. J Mol Pathol 50: 124-131, 1997.
9. 1-adrenergic activation of Na-K-2Cl cotransport. Am J Physiol 273: C1632-C1640, 1997.
10. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K and Silvennoine O, The Bmx tyrosine kinase induces activation of the stat signalling pathway which is specifically inhibited by protein kinase Cδ. Blood 90: 4341-4353, 1997.
11. Basu A, The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257-280, 1993.
12. O'Brian CA, Ward NE, Gravitt KR and Gupta KP, The tumor promoter receptor protein kinase C: A novel target for chemoprevention and therapy of human colon cancer. Prog Clin Biol Res 391: 117-120, 1995.
13. Gescher A, Modulators of signal transduction as cancer chemotherapeutic agents - Novel mechanisms and toxicities. Toxicol Lett 82-83: 159-165, 1995.
14. Caponigro F, French RC and Kaye SB, Protein kinase C: A worthwhile target for anticancer drugs? Anticancer Drugs 8: 26-33, 1997.
15. Pettit GR, Herald CL, Doubek DL and Herald DL, Isolation and structure of bryostatin 1. J Am Chem Soc 104: 6846-6848, 1982.
16. Stone RM, Bryostatin 1: Differentiating agent from the depths. Leuk Res 21: 399-401, 1997.
17. Lorenzo PS, Bögi K, Ács P, Pettit GR and Blumberg PM, The catalytic domain of protein kinase Cδ confers protection from down-regulation induced by bryostatin 1. J Biol Chem 272: 33338-33343, 1997.
18. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR and Hess AD, Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51: 682-687, 1991.
19. Pluda JM, Cheson BD and Phillips PH, Clinical trials referral resource. Clinical trials using bryostatin-1. Oncology 10: 740-742, 1996.
20. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD and Al-Katib AM, Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 16: 56-62, 1998.
21. Mohammad RM, Pettit GR, Almatchy VP, Wall N, Varterasian M and Al-Katib A, Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Anticancer Drugs 9: 149-156, 1998.
22. Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR and Blumberg PM, The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 56-epi-bryostatin 1. Cancer Res 56: 2105-2111, 1996.
23. Bignami GS, Wagner F, Grothaus PG, Rustagi P, Davis DE and Kraft AS, Biological activity of 26-succinylbryostatin 1. Biochim Biophys Acta 1312: 197-206, 1996.
24. Watters D, The bistratenes: Novel tools to study cell growth regulation. In: Progress in Medicinal Chemistry (Ed. Iqbal Choudhary M), Vol. 1, pp. 319-329. Harwood Academic Publishers, Chur, Switzerland, 1996.
25. Garrone B, Kedar P, Elarova I, Lavin M and Watters D, Approaches to determine the specific role of the delta isoform of protein kinase C. J Biochern Biophys Methods 36: 51-61, 1997.
26. Riou D, Roussakis C, Biard JF and Verbist JF, Comparative study of the antitumour activity of bistramides A, D and K against a non-small cell broncho-pulmonary carcinoma. Anticancer Res 13: 2331-2334, 1993.
27. Gouiffes D, Juge M, Grimaud N, Welin L, Sauviat MP, Barbin Y, Laurent D, Roussakis C, Henichart JP and Verbist JF, Bistramide A, a new toxin from the urochordata Lissoclinum bistratum Sluiter: Isolation and preliminary characterization. Toxicon 26: 1129-1136, 1988.
28. Stone RM, Sariban E, Pettit GR and Kufe DW, Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72: 208-213, 1988.
29. Watters D, Marshall K, Hamilton S, Michael J, McArthur MM, Seymour G, Hawkins CJ, Gardiner R and Lavin M, The bistratenes: New cytotoxic marine macrolides which induce some properties indicative of differentiation in HL-60 cells. Biochem Pharmacol 39: 1609-1614, 1990.
30. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR and Kufe DW, Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788, 1995.
31. Takahashi H and Parsons PG, In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: Heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression. Pigment Cell Res 3: 223-232, 1990.
32. Watters D, Garrone B, Coomer J, Johnson WE, Brown G and Parsons P, Stimulation of melanogenesis in a human melanoma cell line by bistratene A. Biochem Pharmacol 55: 1691-1699, 1998.
33. lozumi K, Hoganson GE, Pennella R, Everett MA and Fuller BB, Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol 100: 806811, 1993.
34. Park H-Y, Russakovsky V, Ohno S and Gilchrest B, The β-isoform of protein kinase C stimulates human melanogenesis by activating tyrosinase in pigment cells. J Biol Chem 268: 11742-11749, 1993.
35. Im S, Moro O, Peng F, Medrano EE, Cornelius J, Babcock G, Nordlund JJ and Abdel-Malek ZA, Activation of the cyclic AMP pathway by α-melanotropin mediates the response of human melanocytes to ultraviolet B radiation. Cancer Res 58: 47-54, 1998.
36. Buffey J, Thody AJ, Bleehen SS and Mac Neil S, α-Melanocyte-stimulating hormone stimulates protein kinase C activity in murine B16 melanoma. J Endocrinol 133: 333-340, 1992.
37. Park H-Y, Russakovsky V, Ao Y, Fernandez E and Gilchrest B, α-Melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C. Exp Cell Res 227: 70-79, 1996.
38. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP and Ballotti R, Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 270: 2431524320, 1995.
39. Imagawa M, Chiu R and Karin M, Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell 51: 251-260, 1987.
40. Lee W, Haslinger A, Karin M and Tjian R, Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature 325: 368-372, 1987.
41. Ponnazhagan S, Hou L and Kwon BS, Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Invest Dermatol 102: 744-748, 1994.
42. Sturm RA, Box NF and Ramsay M, Human pigmentation genetics: The difference is only skin deep. Bioessays 20: 712-721, 1998.
43. Rosemblat S, Durham-Pierre D, Gardner JM, Nakatsu Y, Brilliant MH and Orlow SJ, Identification of a melanosomal membrane protein encoded by the pink-eyed dilution (type II oculocutaneous albinism) gene. Proc Nad Acad Sci USA 91: 12071-12075, 1994.
44. Thomson JA, Murphy K, Baker E, Sutherland GR, Parsons PG and Sturm RA, The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11: 691-700, 1995.
45. Eisen T, Easty DJ, Bennett DC and Goding CR, The POU domain transcription factor Brn-2: Elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11: 2157-2164, 1995.
46. Fuse N, Yasumoto KI, Suzuki H, Takahashi K and Shibahara S, Identification of a melanocyte-type promoter of the microphthalmia-associated transcription factor gene. Biochem Biophys Res Commun 219: 702-707, 1996.
47. Yasumoto KI, Yokoyama K, Shibata K, Tomita Y and Shibahara S, Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol 14: 8058-8070, 1994.
48. Bentley NJ, Eisen T and Coding CR, Melanocyte-specific expression of the human tyrosinase promoter: Activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol 14: 7996-8006, 1994.
49. Mahalingam H, Watanabe A, Tachibana M and Niles RM, Characterization of density-dependent regulation of the tyrosinase gene promoter: Role of protein kinase C. Exp Cell Res 237: 83-92, 1997.
50. Clauser KR, Hall SC, Smith DM, Webb JW, Andrews LE, Tran HM, Epstein LB and Burlingame AL, Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc Natl Acad Sci USA 92: 50725076, 1995.
51. Di Paolo G, Pellier V, Catsicas M, Antonsson B, Catsicas S and Grenningloh G, The phosphoprotein stathmin is essential for nerve growth factor-stimulated differentiation. J Cell Biol 133: 1383-1390, 1996.
52. Larsson N, Marklund U, Gradin HM, Brattsand G and Gullberg M, Control of microtubule dynamics by oncoprotein 18: Dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol 17: 5530-5539, 1997.
53. Melander-Gradin H, Larsson N, Marklund U and Gullberg M, Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells. J Cell Biol 140: 131-141, 1998.
54. Curmi PA, Andersen SS, Lachkar S, Gavet O, Karsenti E, Knossow M and Sobel A, The stathmin/tubulin interaction in vitro. J Biol Chem 272: 25029-25036, 1997.
55. Antonsson B, Kassel DB, Di Paolo G, Lutjens R, Riederer BM and Grenningloh G, Identification of in vitro phosphorylation sites in the growth cone protein SCG10. Effect of phosphorylation site mutants on microtubule-destabilizing activity. J Biol Chem 273: 8439-8446, 1998.
56. Mau SE, Saermark T and Vilhardt H, Cross-talk between cellular signaling pathways activated by substance P and vasoactive intestinal peptide in rat lactotroph-enriched pituitary cell cultures. Endocrinology 138: 1704-1711, 1997.
57. Wooten MW, Seibenhener ML, Matthews LH, Zhou G and Coleman ES, Modulation of ζ-protein kinase C by cyclic AMP in PC12 cells occurs through phosphorylation by protein kinase A. J Neurochem 67: 1023-1031, 1996.
58. Scott JD, Dissection of protein kinase and phosphatase targeting interactions. Soc Gen Physiol Ser 52: 227-239, 1997.
59. Marini NJ, Meldrum E, Buehrer B, Hubberstey AV, Stone DE, Traynor-Kaplan A and Reed SI, A pathway in the yeast cell division cycle linking protein kinase C (Pkc1) to activation of Cdc28 at START. EMBO J 15: 3040-3052, 1996.
60. Livneh E and Fishman DD, Linking protein kinase C to cell cycle control. Eur J Biochem 248: 1-9, 1997.
61. Keenan C and Kelleher D, Protein kinase C and the cytoskeleton. Cell Signal 10: 225-232, 1998.
62. Van Lint C, Emiliani S and Verdin E, The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp 5: 245-253, 1996.
63. Schena M, Shalon D, Heller R, Chai A, Brown PO and Davis RW, Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93: 10614-10619, 1996.